Back

Latest Forum Topics / Alset    Last:0.021 --

Post Reply

Singapore-eDev Post Reply Rate topic
wolverine23 Supreme	24-Apr-2020 08:11        wolverine23 About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Medical Bull 2020 !!!!!!!! = Internet Bull 2000 !!!!!!!!"
x 0   x 0  Alert Admin	Emm... This is building up to news. What news? Haha. Guess opening price? johnng      ( Date: 24-Apr-2020 07:59) Posted: Another sell-on news Impact Biomedical&rsquo s Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts   SINGAPORE, 23 April 2020 &ndash Singapore Exchange-listed Singapore eDevelopment Limited&rsquo s (Stock Code 40V) (&ldquo SeD&rdquo ) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical&rsquo s effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). Following encouraging COVID-19 testing results, the groundbreaking technology was independently valued by recognized intellectual property valuation and licensing firm Destum Partners, known globally for its high level of expertise and capability in independently valuing and licensing pharmaceutical technology.  The commercial assessment includes: 3F Biofragrance &ndash a key component of the Open Air Defense Initiative, Equivir - an OTC medication with broad antiviral activity, and Linebacker - a broad-spectrum universal therapeutic. Continuing development of the COVID-19 research program is underway.   This research is part of a multi-year pandemic research program conducted by Impact Biomedical&rsquo s research partner, GRDG Sciences, LLC (&ldquo GRDG&rdquo ), which covers a wide range of solutions to global health issues to adhere to the principles and initiatives established by Project Bioshield and the Biomedical Advanced Research and Development Authority (BARDA).  All three compounds were tested against a rigorous in vitro respiratory virus panel by GRDG, who utilized the non-clinical and pre-clinical services program offered by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.  Previous antimicrobial research was conducted at multiple independent laboratories.  The technology consists of:   &bull 3F Antiviral Biofragrance &ndash 3F Antiviral Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect locations where large numbers of people gather or transit such as airports, containment areas, train stations, convention centers, hospitals, and ports of entry.  The concept is rather than quarantine people from the virus, quarantine the virus from people.  3F Biofragrance technology also provides protection against mosquito-borne diseases such as Zika, Malaria and Dengue fever and is 10-fold more effective than DEET.  3F Mosquito uses other receptor modalities than traditional mosquito repellents to effectively blind humans to mosquitoes.  The Open Air Defense Initiative was created as a solution for Event 201, a pandemic exercise conducted Press Release &ndash Impact Biomedical&rsquo s Next Generation Medical Technologies Valued at $592 Million by Independent Experts   23 April 2020   Page 2 of 4     in 2019 by the Johns Hopkins Center for Health Security, the World Economic Forum and the Bill and Melinda Gates Foundation. Event 201 highlighted areas where public/private partnerships are vital to respond to a severe pandemic.  3F Antiviral Biofragrance is effective against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19.   &bull Equivir &ndash Equivir was created as a solution for Project Bioshield, a U.S. government program to conduct and support research and development activities for countermeasures in biological emergencies.  Equivir is a patented OTC medication that has broad antiviral efficacy against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19.   &bull Linebacker &ndash Linebacker was modeled to shadow the Panacea program created by the US Defense Advanced Research Projects Agency (DARPA).  Panacea was a research program designed to provide novel, multi-target therapeutics for unmet physiological needs.  Linebacker is a patented universal therapeutic medication with demonstrated effectiveness in neurological diseases including Parkinson&rsquo s, multiple histotypes of cancer, and multiple pathogens such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS, MERS, Malaria, and COVID-19.   &bull Laetose - Laetose is a reduced calorie low glycemic sugar replacement created to address the rising global problem of metabolic disorders and associated conditions.   Previous research identified the Angiotensin converting enzyme 2 (&ldquo ACE2&rdquo ) as the host receptor for SARS-CoV-2, the virus causing the COVID-19 pandemic.  Molecular docking conducted by GRDG indicated that Linebacker and Equivir cause a conformational change and modulate the ACE-2 receptor and block three integral viral mechanisms for SARS-CoV-2 replication and infection: the viral spike interaction point, helicase, and protease on the ACE-2 receptor.      &ldquo This professional valuation further validates our technologies, allowing us to move to the next step of engaging in further collaborations to bring things up to speed&rdquo said Mr Chan Heng Fai, Executive Chairman of SeD.    GRDG&rsquo s Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. He said, &ldquo the multiple strategies developed by GRDG to fight global healthcare issues including the recent COVID-19 pandemic are important advances in science to potentially save many lives.&rdquo Press Release &ndash Impact Biomedical&rsquo s Next Generation Medical Technologies Valued at $592 Million by Independent Experts   23 April 2020   Page 3 of 4       Also advising GRDG is Lieutenant Colonel William H. Lyerly Jr., retired Career Senior Executive / Scientific Professional from the U.S. Department of Homeland Security and retired U.S. Army Medical Service Corps Officer.  Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly said, &ldquo GRDG&rsquo s multi-prong strategy to develop and validate different technologies for threats to health is a positive step forward to address many unmet medical needs including the application of evolving novel interventions to address the current Coronavirus pandemic.&rdquo   Daryl Thompson, Director of Scientific Initiatives and founder of GRDG said, &ldquo We are proud of the Impact Biomedical research team and the successful accomplishment of a 5 year research and development project focused on the identification and proving of viable biodefense countermeasures as outlined in the Pandemic and All Hazards Preparedness Act established in 2006.   &ldquo Moving ahead we are looking forward to another series of research focused on developing global viral mitigation and control technologies for scenarios such as the current COVID-19 outbreak, the development of novel antiviral therapeutics, as well as addressing solutions for the impending &lsquo patent cliff&rsquo crisis expected in 2024.   &ldquo Impact Biomedical and its research partner Global Research and Discovery Group Sciences will work with leading global policy makers to establish specially created research teams focused exclusively on &lsquo difficult to achieve&rsquo or nearly impossible projects utilizing lessons learned from our previous projects.&rdquo   Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should tak
Useful To Me  Not Useful To Me
johnng Supreme	24-Apr-2020 07:59        johnng About Contact  Quote this Post!
x 0   x 0  Alert Admin	Another sell-on news Impact Biomedical&rsquo s Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts   SINGAPORE, 23 April 2020 &ndash Singapore Exchange-listed Singapore eDevelopment Limited&rsquo s (Stock Code 40V) (&ldquo SeD&rdquo ) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical&rsquo s effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). Following encouraging COVID-19 testing results, the groundbreaking technology was independently valued by recognized intellectual property valuation and licensing firm Destum Partners, known globally for its high level of expertise and capability in independently valuing and licensing pharmaceutical technology.  The commercial assessment includes: 3F Biofragrance &ndash a key component of the Open Air Defense Initiative, Equivir - an OTC medication with broad antiviral activity, and Linebacker - a broad-spectrum universal therapeutic. Continuing development of the COVID-19 research program is underway.   This research is part of a multi-year pandemic research program conducted by Impact Biomedical&rsquo s research partner, GRDG Sciences, LLC (&ldquo GRDG&rdquo ), which covers a wide range of solutions to global health issues to adhere to the principles and initiatives established by Project Bioshield and the Biomedical Advanced Research and Development Authority (BARDA).  All three compounds were tested against a rigorous in vitro respiratory virus panel by GRDG, who utilized the non-clinical and pre-clinical services program offered by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.  Previous antimicrobial research was conducted at multiple independent laboratories.  The technology consists of:   &bull 3F Antiviral Biofragrance &ndash 3F Antiviral Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect locations where large numbers of people gather or transit such as airports, containment areas, train stations, convention centers, hospitals, and ports of entry.  The concept is rather than quarantine people from the virus, quarantine the virus from people.  3F Biofragrance technology also provides protection against mosquito-borne diseases such as Zika, Malaria and Dengue fever and is 10-fold more effective than DEET.  3F Mosquito uses other receptor modalities than traditional mosquito repellents to effectively blind humans to mosquitoes.  The Open Air Defense Initiative was created as a solution for Event 201, a pandemic exercise conducted Press Release &ndash Impact Biomedical&rsquo s Next Generation Medical Technologies Valued at $592 Million by Independent Experts   23 April 2020   Page 2 of 4     in 2019 by the Johns Hopkins Center for Health Security, the World Economic Forum and the Bill and Melinda Gates Foundation. Event 201 highlighted areas where public/private partnerships are vital to respond to a severe pandemic.  3F Antiviral Biofragrance is effective against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19.   &bull Equivir &ndash Equivir was created as a solution for Project Bioshield, a U.S. government program to conduct and support research and development activities for countermeasures in biological emergencies.  Equivir is a patented OTC medication that has broad antiviral efficacy against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19.   &bull Linebacker &ndash Linebacker was modeled to shadow the Panacea program created by the US Defense Advanced Research Projects Agency (DARPA).  Panacea was a research program designed to provide novel, multi-target therapeutics for unmet physiological needs.  Linebacker is a patented universal therapeutic medication with demonstrated effectiveness in neurological diseases including Parkinson&rsquo s, multiple histotypes of cancer, and multiple pathogens such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS, MERS, Malaria, and COVID-19.   &bull Laetose - Laetose is a reduced calorie low glycemic sugar replacement created to address the rising global problem of metabolic disorders and associated conditions.   Previous research identified the Angiotensin converting enzyme 2 (&ldquo ACE2&rdquo ) as the host receptor for SARS-CoV-2, the virus causing the COVID-19 pandemic.  Molecular docking conducted by GRDG indicated that Linebacker and Equivir cause a conformational change and modulate the ACE-2 receptor and block three integral viral mechanisms for SARS-CoV-2 replication and infection: the viral spike interaction point, helicase, and protease on the ACE-2 receptor.      &ldquo This professional valuation further validates our technologies, allowing us to move to the next step of engaging in further collaborations to bring things up to speed&rdquo said Mr Chan Heng Fai, Executive Chairman of SeD.    GRDG&rsquo s Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. He said, &ldquo the multiple strategies developed by GRDG to fight global healthcare issues including the recent COVID-19 pandemic are important advances in science to potentially save many lives.&rdquo Press Release &ndash Impact Biomedical&rsquo s Next Generation Medical Technologies Valued at $592 Million by Independent Experts   23 April 2020   Page 3 of 4       Also advising GRDG is Lieutenant Colonel William H. Lyerly Jr., retired Career Senior Executive / Scientific Professional from the U.S. Department of Homeland Security and retired U.S. Army Medical Service Corps Officer.  Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly said, &ldquo GRDG&rsquo s multi-prong strategy to develop and validate different technologies for threats to health is a positive step forward to address many unmet medical needs including the application of evolving novel interventions to address the current Coronavirus pandemic.&rdquo   Daryl Thompson, Director of Scientific Initiatives and founder of GRDG said, &ldquo We are proud of the Impact Biomedical research team and the successful accomplishment of a 5 year research and development project focused on the identification and proving of viable biodefense countermeasures as outlined in the Pandemic and All Hazards Preparedness Act established in 2006.   &ldquo Moving ahead we are looking forward to another series of research focused on developing global viral mitigation and control technologies for scenarios such as the current COVID-19 outbreak, the development of novel antiviral therapeutics, as well as addressing solutions for the impending &lsquo patent cliff&rsquo crisis expected in 2024.   &ldquo Impact Biomedical and its research partner Global Research and Discovery Group Sciences will work with leading global policy makers to establish specially created research teams focused exclusively on &lsquo difficult to achieve&rsquo or nearly impossible projects utilizing lessons learned from our previous projects.&rdquo   Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should tak
Useful To Me  Not Useful To Me
oreocookie Senior	23-Apr-2020 23:54        oreocookie About Contact  Quote this Post!
x 0   x 0  Alert Admin	DSS stock rocketing on NYSE.... is this due to the valuation report?
Useful To Me  Not Useful To Me
Trojan Member	23-Apr-2020 22:05        Trojan About Contact  Quote this Post!
x 0   x 0  Alert Admin	Wonder how much financial benefit SED is going to reap from this few hundred million valuation tied to Impact BioMedical which will be ?disposed? to DSS BioHealth under the USD50 million agreement. Probably depends on the number of DSS BioHealth shares that will be allocated to SED eventually. The agreement is rather complex as follows. https://links.sgx.com/FileOpen/SeD-Ann-ProposedShareSwap-EntryintoTermSheet.ashx?App=Announcement&FileID=600661
Useful To Me  Not Useful To Me
gregtan123 Supreme	23-Apr-2020 20:54        gregtan123 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Bro SGX market have to deal with NOISE esp the SHORTS. the shorts are EXTREMELY POWERFUL. EVEN if you have stars aligned, if BB shorts want u to down, u also down. Ryuuenji      ( Date: 23-Apr-2020 20:41) Posted: Good to hear that. .. Just try to avoid hearing noise and concentrate on what your intuition is telling you. gregtan123      ( Date: 23-Apr-2020 20:32) Posted: I think for me I better dont chase. I just hope u HUAT also. I made some money the last 2 days from the medical bull. Now medical bull become medical bear cause of the STUPID BIOlidics. Now sentiment down. I still got 15-20k stuck in other medical counters but lucky bought not high
Useful To Me  Not Useful To Me
Ryuuenji Elite	23-Apr-2020 20:41        Ryuuenji About Contact  Quote this Post!
x 0   x 0  Alert Admin	Good to hear that. .. Just try to avoid hearing noise and concentrate on what your intuition is telling you. gregtan123      ( Date: 23-Apr-2020 20:32) Posted: I think for me I better dont chase. I just hope u HUAT also. I made some money the last 2 days from the medical bull. Now medical bull become medical bear cause of the STUPID BIOlidics. Now sentiment down. I still got 15-20k stuck in other medical counters but lucky bought not high. Ryuuenji      ( Date: 23-Apr-2020 20:30) Posted: Bro, not possible to open at 0.08.. I brought really low, so I don' t bother to sell and rather take a risk. Biolidics spoilt the everyone' s dream. I was expecting it to break free from 0.053.. nevertheless we hope tomorrow' s opening a good one. Hope you will have a happy catch.
Useful To Me  Not Useful To Me
gregtan123 Supreme	23-Apr-2020 20:32        gregtan123 About Contact  Quote this Post!
x 0   x 0  Alert Admin	I think for me I better dont chase. I just hope u HUAT also. I made some money the last 2 days from the medical bull. Now medical bull become medical bear cause of the STUPID BIOlidics. Now sentiment down. I still got 15-20k stuck in other medical counters but lucky bought not high. Ryuuenji      ( Date: 23-Apr-2020 20:30) Posted: Bro, not possible to open at 0.08.. I brought really low, so I don' t bother to sell and rather take a risk. Biolidics spoilt the everyone' s dream. I was expecting it to break free from 0.053.. nevertheless we hope tomorrow' s opening a good one. Hope you will have a happy catch. gregtan123      ( Date: 23-Apr-2020 20:15) Posted: That' s true. Bro Ryuuenji are you in? ALso i saw hte news early, didnt share cause i wanted to renter at 4. Sold all today at 4.8 average. tot i was a genius BUT then this share likely open 8 cent tomorrow
Useful To Me  Not Useful To Me
Ryuuenji Elite	23-Apr-2020 20:30        Ryuuenji About Contact  Quote this Post!
x 0   x 0  Alert Admin	Bro, not possible to open at 0.08.. I brought really low, so I don' t bother to sell and rather take a risk. Biolidics spoilt the everyone' s dream. I was expecting it to break free from 0.053.. nevertheless we hope tomorrow' s opening a good one. Hope you will have a happy catch. gregtan123      ( Date: 23-Apr-2020 20:15) Posted: That' s true. Bro Ryuuenji are you in? ALso i saw hte news early, didnt share cause i wanted to renter at 4. Sold all today at 4.8 average. tot i was a genius BUT then this share likely open 8 cent tomorrow? Ryuuenji      ( Date: 23-Apr-2020 20:01) Posted: Even at 0.04, how much can you lose compared to Biolidics from 0.80
Useful To Me  Not Useful To Me
gregtan123 Supreme	23-Apr-2020 20:28        gregtan123 About Contact  Quote this Post!
x 0   x 0  Alert Admin	No la, news is AFTER market, how I see? I sold today 400,000 share stuck high 0.0412 average last time, sold 0.0484 average.  Then go back to 3.9 n 4.0 never dare buy back. wanted to buy back 0.033 tomorrow lor then AFTER market this news. I am tempted to CHASE tomorrow BUT BUT BUT I learn the Medtec lesson + Saw today Biolidics event 0.885 half to 0.425 so I decided tomorrow dont chase. Max Hand Itchy chas 100,000 but cut loss at 15%. commando      ( Date: 23-Apr-2020 20:23) Posted: U saw the news earlier but sold? Oh gregtan123      ( Date: 23-Apr-2020 20:15) Posted: That' s true. Bro Ryuuenji are you in? ALso i saw hte news early, didnt share cause i wanted to renter at 4. Sold all today at 4.8 average. tot i was a genius BUT then this share likely open 8 cent tomorrow
Useful To Me  Not Useful To Me
Gknight Senior	23-Apr-2020 20:24        Gknight About Contact  Quote this Post!
x 0   x 0  Alert Admin	depend bb want play anot.. bb want play shoot to 0.1 also possible.
Useful To Me  Not Useful To Me
commando Master	23-Apr-2020 20:23        commando About Contact  Quote this Post!
x 0   x 0  Alert Admin	U saw the news earlier but sold? Oh gregtan123      ( Date: 23-Apr-2020 20:15) Posted: That' s true. Bro Ryuuenji are you in? ALso i saw hte news early, didnt share cause i wanted to renter at 4. Sold all today at 4.8 average. tot i was a genius BUT then this share likely open 8 cent tomorrow? Ryuuenji      ( Date: 23-Apr-2020 20:01) Posted: Even at 0.04, how much can you lose compared to Biolidics from 0.80
Useful To Me  Not Useful To Me
gregtan123 Supreme	23-Apr-2020 20:15        gregtan123 About Contact  Quote this Post!
x 0   x 0  Alert Admin	That' s true. Bro Ryuuenji are you in? ALso i saw hte news early, didnt share cause i wanted to renter at 4. Sold all today at 4.8 average. tot i was a genius BUT then this share likely open 8 cent tomorrow? Ryuuenji      ( Date: 23-Apr-2020 20:01) Posted: Even at 0.04, how much can you lose compared to Biolidics from 0.80
Useful To Me  Not Useful To Me
wolverine23 Supreme	23-Apr-2020 20:14        wolverine23 About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Medical Bull 2020 !!!!!!!! = Internet Bull 2000 !!!!!!!!"
x 0   x 0  Alert Admin	not buying to lose. buy to sell at 0.80 :) Ryuuenji      ( Date: 23-Apr-2020 20:01) Posted: Even at 0.04, how much can you lose compared to Biolidics from 0.80
Useful To Me  Not Useful To Me
Ryuuenji Elite	23-Apr-2020 20:01        Ryuuenji About Contact  Quote this Post!
x 0   x 0  Alert Admin	Even at 0.04, how much can you lose compared to Biolidics from 0.80
Useful To Me  Not Useful To Me
wolverine23 Supreme	23-Apr-2020 19:47        wolverine23 About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Medical Bull 2020 !!!!!!!! = Internet Bull 2000 !!!!!!!!"
x 0   x 0  Alert Admin	ya, this is still a low range price.... lets see if can collect more or gap up pass 5? SmallSmall      ( Date: 23-Apr-2020 19:41) Posted: Which is why you have to buy when the price is still low. Just the same for Biolidics and so on. Not when the whole world already knew it nqing87      ( Date: 23-Apr-2020 19:20) Posted: i have to question the objective of this announcement.. to stir up share price? it is because of these valuators that so many medical or tech start-up are valued so highly and has an sky high IPO price
Useful To Me  Not Useful To Me
SmallSmall Supreme	23-Apr-2020 19:41        SmallSmall About Contact  Quote this Post!
x 0   x 0  Alert Admin	Which is why you have to buy when the price is still low. Just the same for Biolidics and so on. Not when the whole world already knew it nqing87      ( Date: 23-Apr-2020 19:20) Posted: i have to question the objective of this announcement.. to stir up share price? it is because of these valuators that so many medical or tech start-up are valued so highly and has an sky high IPO price
Useful To Me  Not Useful To Me
wolverine23 Supreme	23-Apr-2020 19:39        wolverine23 About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Medical Bull 2020 !!!!!!!! = Internet Bull 2000 !!!!!!!!"
x 0   x 0  Alert Admin	&ldquo This professional valuation further validates our technologies, allowing us to move to the next step of engaging in further collaborations to bring things up to speed&rdquo said Mr Chan Heng Fai, Executive Chairman of SeD.    key phrase: " bring things up to speed" Dont miss!
Useful To Me  Not Useful To Me
wolverine23 Supreme	23-Apr-2020 19:28        wolverine23 About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Medical Bull 2020 !!!!!!!! = Internet Bull 2000 !!!!!!!!"
x 0   x 0  Alert Admin	lets do another biolidics with this. all the way to $0.885! Sgvale      ( Date: 23-Apr-2020 19:25) Posted: SeD is of more substance. It is green when others had plunged. Nevertheless, it's rise is also eased affected by the market mood. oreocookie      ( Date: 23-Apr-2020 19:14) Posted: SED just released. Their subsidiary Impact Bio valuation of their IPs https://links.sgx.com/FileOpen/SeD-PR-Valuation_Impact_BioMedical.ashx?App=Announcement& FileID=607811 US$592 Million !
Useful To Me  Not Useful To Me
Sgvale Supreme	23-Apr-2020 19:25        Sgvale About Contact  Quote this Post!
x 0   x 0  Alert Admin	SeD is of more substance. It is green when others had plunged. Nevertheless, it's rise is also eased affected by the market mood. oreocookie      ( Date: 23-Apr-2020 19:14) Posted: SED just released. Their subsidiary Impact Bio valuation of their IPs https://links.sgx.com/FileOpen/SeD-PR-Valuation_Impact_BioMedical.ashx?App=Announcement& FileID=607811 US$592 Million !
Useful To Me  Not Useful To Me
ErosValkyrie Member	23-Apr-2020 19:23        ErosValkyrie About Contact  Quote this Post!
x 0   x 0  Alert Admin	will watch this tmr
Useful To Me  Not Useful To Me

                                                         First   < Newer   7741-7760 of 8048   Older>   Last